Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RLAY vs SANA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RLAY Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 5–2 Matrix Metrics)

RLAY Overall Winner 6-Pillar Tally: RLAY 3 – 1 SANA (2 Tie) Matrix Metrics: RLAY 5 – 2 SANA

As of Nov 16, 2026, Relay Therapeutics, Inc. (RLAY) is the stronger overall head-to-head candidate over Sana Biotechnology, Inc. (SANA) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). RLAY carries a Unified Composite Score of 50.0/100 (HOLD) at $17.27 (N/M Forward P/E, -3094.6% operating margin), whereas SANA carries 44.3/100 (HOLD) at $1.88 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: RLAY earns the overall head-to-head edge with a stronger Unified Composite Score (50.0/100 HOLD vs. SANA 44.3/100 HOLD) and 1.70β · 78% Vol risk profile, whereas SANA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: RLAY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.8); meanwhile SANA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RLAY vs SANA
RLAY NASDAQ Head-to-Head Winner
Relay Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$17.27
-4.53% 1D
Market Cap $4.0B
TTM Revenue $10M
Forward P/E N/M
Beta / 30D Vol 1.70β · 78% Vol
Unified Composite Score
50.0 / 100 HOLD
Tech 48.0 Fund 55.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.4%), weak momentum, RSI 45
RSI-14: 44.8 · SMA20: $18.49 · SMA50: $18.34
SANA NASDAQ
Sana Biotechnology, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.88
-6.93% 1D
Market Cap $605.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.82β · 78% Vol
Unified Composite Score
44.3 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 66.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.0%), weak momentum, RSI 31
RSI-14: 30.6 · SMA20: $2.37 · SMA50: $2.68

6-Pillar Scorecard Institutional Category Breakdown (RLAY 3 – 1 SANA)

Columns: Metric · RLAY · SANA
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale RLAY
Revenue Growth (YoY) -48.3% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $10M N/A
Market Cap $4.0B $605.3M
3. Profitability & Quality SANA
Gross Margin N/A N/A
Operating Margin -3094.6% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -41.2% -79.5%
4. Balance Sheet & Cash Flow RLAY
Cash Generation (TTM) -$214M -$145M
Cash Flow Margin N/A N/A
Net Cash / Leverage $97M Net Cash $13M Net Debt (0.30x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RLAY
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 68.6% (6th %ile) 105.5% (4th %ile)
Put/Call OI Skew 0.99x (Balanced) 0.61x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RLAY (5) vs SANA (2)
Institutional Metric RLAY SANA Criterion Row Edge
Market Capitalization
Scale
$4.0B $605.3M Larger Scale RLAY
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-48.3% +0.0% Higher Growth SANA
Operating Margin (TTM)
Profitability
-3094.6% 0.0% Higher Margin SANA
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-41.2% -79.5% Higher ROE RLAY
52-Week Range Position
Momentum
74% ($6–$21) 1% ($2–$5) Stronger Trend RLAY
Beta / 30D Volatility
Risk Regime
1.70β · 78% Vol 1.82β · 78% Vol Lower Realized Risk RLAY
Unified Institutional Score
Composite Signal
50.0 / 100 (HOLD) 44.3 / 100 (HOLD) Higher Composite RLAY
Trailing 12M Revenue (USD)
Operating Scale
$10M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$214M ($97M Net Cash) -$145M ($13M Net Debt (0.30x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RLAY +23.26 pp
RLAY: +6.08% · SANA: -17.18%
3M Horizon RLAY +32.0 pp
RLAY: -16.21% · SANA: -48.21%
6M Horizon RLAY +80.89 pp
RLAY: +42.73% · SANA: -38.16%
1Y Horizon RLAY +216.38 pp
RLAY: +167.75% · SANA: -48.63%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RLAY vs SANA. Trailing 12-month operating profitability (RLAY -3094.6% vs SANA 0.0%) and valuation multiples (RLAY N/M vs SANA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

RLAY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$10M
Gross MarginN/A
Op. Margin-3094.6%
ROE / Fwd P/E-41.2% · N/M
SANA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-79.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RLAY CONSOLIDATION
101d in phase · OBV NEUTRAL
Current IV 68.6%
IV Percentile 6th %ile
Put/Call OI Skew 0.99x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RLAY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SANA BREAKDOWN
57d in phase · OBV NEUTRAL
Current IV 105.5%
IV Percentile 4th %ile
Put/Call OI Skew 0.61x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SANA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RLAY Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.0B market capitalization and -3094.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SANA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $605.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RLAY vs SANA Key Questions & Quantitative Answers

As of Nov 16, 2026, Relay Therapeutics, Inc. (RLAY) is the stronger overall head-to-head candidate over Sana Biotechnology, Inc. (SANA) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). RLAY carries a Unified Composite Score of 50.0/100 (HOLD) at $17.27 (N/M Forward P/E, -3094.6% operating margin), whereas SANA carries 44.3/100 (HOLD) at $1.88 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: RLAY earns the overall head-to-head edge with a stronger Unified Composite Score (50.0/100 HOLD vs. SANA 44.3/100 HOLD) and 1.70β · 78% Vol risk profile, whereas SANA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: RLAY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.8); meanwhile SANA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RLAY leads the Growth & Scale pillar: RLAY posts -48.3% YoY revenue growth and +0.0% YoY earnings growth on $10M TTM revenue (N/A gross margin, -3094.6% operating margin), compared with SANA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, RLAY generates $10M in USD-normalized revenue versus N/A for SANA. In operating R&D and SG&A reinvestment, RLAY deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SANA.

RLAY and SANA trade at balanced relative valuation multiples. RLAY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas SANA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RLAY (-41.2% ROE) versus SANA (-79.5% ROE) capital efficiency.

In options market volatility and institutional positioning, RLAY carries 68.6% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.99x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.70β · 78% Vol realized risk). By comparison, SANA carries 105.5% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.61x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.